OCGN - Ocugen Inc Stock Price, Fair Value and News

$1.14+0.02 (+1.79%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OCGN RSI Chart

OCGN Valuation

Market Cap

322.4M

Price/Earnings (Trailing)

-6.46

Price/Sales (Trailing)

44.39

EV/EBITDA

-5.15

Price/Free Cashflow

-5.92

OCGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OCGN Fundamentals

OCGN Revenue

Revenue (TTM)

7.3M

Rev. Growth (Yr)

60.3%

Rev. Growth (Qtr)

-61.91%

OCGN Earnings

Earnings (TTM)

-49.9M

Earnings Growth (Yr)

33.75%

Earnings Growth (Qtr)

-28.14%

OCGN Price Action

Last 7 days

-8.9%

Last 30 days

-13.2%

Last 90 days

-12.5%

Trailing 12 Months

180%

OCGN Profitability

EBT Margin

-953.45%

Return on Equity

-294.74%

Return on Assets

-123.06%

Free Cashflow Yield

-16.89%

OCGN Financial Health

Current Ratio

1.04

Debt/Equity

0.09

Debt/Cashflow

-29.33

OCGN Investor Care

Shares Dilution (1Y)

12.23%

Diluted EPS (TTM)

-0.17

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.6M	7.3M	0	0
2023	2.4M	2.3M	5.5M	6.0M
2022	654.3K	1.3M	1.9M	2.5M
2020	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

CEO	Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
WEBSITE	ocugen.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	84

Ocugen Inc Frequently Asked Questions

What is the ticker symbol for Ocugen Inc? What does OCGN stand for in stocks?

OCGN is the stock ticker symbol of Ocugen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocugen Inc (OCGN)?

As of Wed Sep 18 2024, market cap of Ocugen Inc is 322.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers.

Is Ocugen Inc a good stock to buy?

The fair value guage provides a quick view whether OCGN is over valued or under valued. Whether Ocugen Inc is cheap or expensive depends on the assumptions which impact Ocugen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCGN.

What is Ocugen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, OCGN's PE ratio (Price to Earnings) is -6.46 and Price to Sales (PS) ratio is 44.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCGN PE ratio will change depending on the future growth rate expectations of investors.